Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer We performed paired NGS of tumor DNA and plasma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results